Table 1.
Baseline demographics and pretreatment clinical courses
| Variable | All patients (n = 305) | Seizure (n = 26) | Nonseizure (n = 279) | P value |
|---|---|---|---|---|
| Age, median (IQR) | 64.0 (55.0, 70.0) | 59.0 (55.0, 69.0) | 64.0 (55.0, 70.0) | .348 |
| Female sex, n (%) | 189 (62.0) | 15 (57.7) | 174 (62.4) | .676 |
| KPS pre-SRS, median (IQR) | 80.0 (80.0, 90.0) | 90.0 (80.0, 90.0) | 80.0 (80.0, 90.0) | .360 |
| Pre-SRS neurologic symptoms, n (%) | 124 (40.7) | 18 (69.2) | 106 (38.0) | .003 |
| Pre-SRS steroids, n (%) | 127 (41.6) | 17 (65.4) | 110 (39.4) | .012 |
| Prior craniotomy, n (%) | 78 (25.6) | 9 (34.6) | 69 (24.7) | .346 |
| Prior WBRT, n (%) | 39 (12.8) | 2 (7.7) | 37 (13.3) | .551 |
| Pre-SRS immunotherapy, n (%) | 35 (11.5) | 6 (23.1) | 29 (10.4) | .097 |
| Pre-SRS chemotherapy, n (%) | 106 (34.8) | 12 (46.2) | 94 (33.7) | .205 |
| Cerebellar involvement, n (%) | 99 (32.5) | 4 (15.4) | 95 (34.1) | .077 |
| Brain stem involvement, n (%) | 34 (11.1) | 3 (11.5) | 31 (11.1) | 1.0 |
| Location of largest treated lesion, n (%) | .418 | |||
| Frontal | 100 (32.8) | 8 (30.8) | 92 (33.3) | |
| Cerebellum | 68 (22.3) | 4 (15.3) | 64 (23.2) | |
| Parietal | 47 (15.4) | 8 (30.8) | 39 (14.1) | |
| Temporal | 31 (10.2) | 2 (7.7) | 29 (10.5) | |
| Occipital | 30 (9.8) | 1 (3.8) | 29 (10.5) | |
| Deep | 14 (4.6) | 1 (3.8) | 13 (4.7) | |
| Brain stem | 10 (3.3) | 1 (3.8) | 9 (3.3) | |
| Extra-axial | 5 (1.6) | 1 (3.8) | 4 (1.4) | |
| Histology, n (%) | ||||
| Melanoma | 44 (14.4) | 5 (19.2) | 39 (14.0) | |
| NSCLC | 161 (52.8) | 7 (26.9) | 154 (55.2) | |
| RCC | 22 (7.2) | 4 (15.4) | 18 (6.5) | |
| SCLC | 7 (2.3) | 0 (0.0) | 7 (2.5) | |
| Breast | 44 (14.4) | 5 (19.2) | 39 (14.0) | |
| Other | 27 (8.9) | 5 (19.2) | 22 (7.9) |
Abbreviations: AED = antiepileptic drug; IQR = interquartile range; KPS = Karnofsky Performance Scale score; NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma; SCLC = small cell lung cancer; SRS = stereotactic radiosurgery; WBRT = whole brain radiation therapy.
Values in boldface are statistically significant.